Inventor
RIKOVA KLARISA
US28 patents
⚠️ This page may combine multiple inventors who share the name “RIKOVA KLARISA”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
BLUEFIN BIOMEDICINE INC
12 patentsUS12138314B2Nov 12, 2024
Anti-CUB domain-containing protein 1 (CDCP1) antibodies, antibody drug conjugates, and methods of use thereof
BLUEFIN BIOMEDICINE INC1 citations71
US12138313B2Nov 12, 2024
Anti-cub domain-containing protein 1 (CDCP1) antibodies, antibody drug conjugates, and methods of use thereof
BLUEFIN BIOMEDICINE INC1 citations71
US11702481B2Jul 18, 2023
Anti-cub domain-containing protein 1 (CDCP1) antibodies, antibody drug conjugates, and methods of use thereof
BLUEFIN BIOMEDICINE INC3 citations71
US11981732B2May 14, 2024
Anti-TMEFF1 antibodies and antibody drug conjugates
BLUEFIN BIOMEDICINE INC1 citations70
US11634486B2Apr 25, 2023
Anti-SEZ6L2 antibodies and antibody drug conjugates
BLUEFIN BIOMEDICINE INC3 citations70
US11312769B2Apr 26, 2022
Anti-TMEFF1 antibodies and antibody drug conjugates
BLUEFIN BIOMEDICINE INC4 citations70
US12491256B2Dec 9, 2025
Anti-cub domain-containing protein 1 (CDCP1) antibodies, antibody drug conjugates, and methods of use thereof
BLUEFIN BIOMEDICINE INC0 citations60
US12473358B2Nov 18, 2025
Anti-TMEFF1 antibodies and antibody drug conjugates
BLUEFIN BIOMEDICINE INC0 citations59
US12296006B2May 13, 2025
Anti-LY6H antibodies and antibody drug conjugates
BLUEFIN BIOMEDICINE INC0 citations59
US11434303B2Sep 6, 2022
Anti-LY6H antibodies and antibody drug conjugates
BLUEFIN BIOMEDICINE INC1 citations59
US12110326B2Oct 8, 2024
Anti-ILT3 antibodies and antibody drug conjugates
BLUEFIN BIOMEDICINE INC0 citations57
US11267886B2Mar 8, 2022
Anti-ILT3 antibodies and antibody drug conjugates
BLUEFIN BIOMEDICINE INC1 citations57
CELL SIGNALING TECHNOLOGY INC
10 patentsUS7700339B2Apr 20, 2010
Gene defects and mutant ALK kinase in human solid tumors
CELL SIGNALING TECHNOLOGY INC22 citations92
US8377642B2Feb 19, 2013
Gene defects and mutant ALK kinase in human solid tumors
CELL SIGNALING TECHNOLOGY INC5 citations83
US11505833B2Nov 22, 2022
Compositions for detecting mutant anaplastic lymphoma kinase in lung cancer
CELL SIGNALING TECHNOLOGY INC0 citations62
US10955416B2Mar 23, 2021
Compositions for detecting mutant anaplastic lymphoma kinase in human lung cancer
CELL SIGNALING TECHNOLOGY INC0 citations62
US9988688B2Jun 5, 2018
Compositions for detecting mutant anaplastic lymphoma kinase in lung cancer
CELL SIGNALING TECHNOLOGY INC1 citations62
US9523130B2Dec 20, 2016
Methods of treating non-small cell lung carcinoma (NSCLC)
CELL SIGNALING TECHNOLOGY INC1 citations62
US7932044B2Apr 26, 2011
Identification of non-small cell lung carcinoma (NSCLC) tumors expressing PDGFR-α
CELL SIGNALING TECHNOLOGY INC2 citations59
US10870892B2Dec 22, 2020
Compositions for detecting mutant anaplastic lymphoma kinase in lung cancer
CELL SIGNALING TECHNOLOGY INC0 citations51
US7977462B2Jul 12, 2011
Tyrosine phosphorylation sites
CELL SIGNALING TECHNOLOGY INC1 citations47
US7807789B2Oct 5, 2010
Reagents for the detection of protein phosphorylation in EGFR-signaling pathways
CELL SIGNALING TECHNOLOGY INC1 citations47
RIKOVA KLARISA
6 patentsUS8481279B2Jul 9, 2013
Methods of treating lung cancer using inhibitors anaplastic lymphoma kinase
RIKOVA KLARISA6 citations83
US8232060B2Jul 31, 2012
Gene defects and mutant ALK kinase in human solid tumors
RIKOVA KLARISA6 citations82
US8288102B2Oct 16, 2012
Gene defects and mutant ALK kinase in human solid tumors
RIKOVA KLARISA5 citations72
US8168383B2May 1, 2012
Gene defects and mutant ALK kinase in human solid tumors
RIKOVA KLARISA5 citations72
US8486645B2Jul 16, 2013
Gene defects and mutant ALK kinase in human solid tumors
RIKOVA KLARISA2 citations61
US8466160B2Jun 18, 2013
Identification of non-small cell lung carcinoma (NSCLC) tumors expressing PDGFR-alpha
RIKOVA KLARISA1 citations45